NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
4 trialsNCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT06083662 2025-03-18
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
Phase 2 Completed
NCT01670877 2022-04-15
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
Phase 2 Completed